Anson Funds Management’s Bionano Genomics BNGO Stock Holding History

Anson Funds Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-42	Closed	-$77K	–	258
2020 Q4	$77K	Buy	+42	New	+$15.7K	0.02%	167

Other funds holding BNGO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Anson Funds Management's BNGO Position: Q1 2021 in Review

Anson Funds Management sold out of Bionano Genomics (BNGO) in Q1 2021, closing a stake of 42 shares — an estimated $77K sold.

Anson Funds Management first reported a position in BNGO in Q4 2020 and held it in 1 quarter. The position peaked at $77K in Q4 2020. 109 funds tracked by Wall St. Rank hold BNGO as of Q1 2021.

Anson Funds Management reported no remaining Bionano Genomics position as of Q1 2021 after selling out during the quarter.
Anson Funds Management sold 42 Bionano Genomics shares in Q1 2021, an estimated $77K.
Anson Funds Management first reported a position in Bionano Genomics in Q4 2020 and held it in 1 quarter.
Anson Funds Management's Bionano Genomics position peaked at $77K in Q4 2020.
109 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.